Table 1.
Patient characteristics.
| Patient # | Age (y) | sex | MS type | DMT | EDSS | Comorbidities/other risk factors | 1st/2nd vaccination date | Vaccine type | 3rd vaccination date | Vaccine type | 1st casirivimab/imdevimab | 2nd casirivimab/imdevimab | 1st sotrovimab | 1st tixagevimab/cilgavimab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 63 | m | SPMS | SIP | 6.0 | normocytic anemia | 22 Feb 2021 | BNT162b2 | 30 Jul 2021 | BNT162b2 | 16 Dec 2021 | 13 Jan 2022 | 10 Feb 2022 | 7 Apr 2022 |
| 15 Mar 2021 | BNT162b2 | |||||||||||||
| 2 | 54 | m | RRMS | FTY | 2.0 | wife with breast cancer on chemo- and radiotherapy | 5 Apr 2021 | BNT162b2 | 21 Sep 2021 | BNT162b2 | 17 Dec 2021 | 14 Jan 2022 | 11 Feb 2022 | 8 Apr 2022 |
| 26 Apr 2021 | BNT162b2 | |||||||||||||
| 3 | 50 | m | RRMS | FTY | 2.0 | suspected arterial hypertension | 15 May 2021 | BNT162b2 | 4 Nov 2021 | mRNA-1273 | 10 Jan 2022 | none | 7 Feb 2022 | 4 Apr 2022 |
| 5 Jun 2021 | BNT162b2 | |||||||||||||
| 4 | 65 | f | RRMS | FTY | 4.0 | arterial hypertension; hypercholesterolemia; autoimmune thyroiditis; slight overweight | 5 May 2021 | BNT162b2 | 3 Dec 2021 | mRNA-1273 | 10 Jan 2022 | none | 7 Feb 2022 | 4 Apr 2022 |
| 9 Jun 2021 | BNT162b2 | |||||||||||||
| 5 | 64 | m | RRMS | FTY | 2.0 | basal cell carcinoma, excision Sep and Oct 2021; hypercholesterolemia | 2 May 2021 | AZD1222 | 23 Nov 2021 | BNT162b2 | 12 Jan 2022 | none | 9 Feb 2022 | 6 Apr 2022 |
| 29 Jun 2021 | BNT162b2 | |||||||||||||
| 6 | 44 | f | RRMS | FTY | 1.5 | 3 school-age children | 22 Mar 2021 | AZD1222 | 23 Sep 2021 | mRNA-1273 | 14 Jan 2022 | none | 11 Feb 2022 | 8 Apr 2022 |
| 18 Jun 2021 | BNT162b2 |
y, years; m, male; f, female; MS, multiple sclerosis; SPMS, secondary progressive MS; RRMS, relapsing-remitting MS; DMT, disease-modifying treatment; SIP, siponimod; FTY, fingolimod; EDSS, Expanded Disability Status Scale.